This from BiG has just become the crux of a piece that someone will pay me for:
r, US pricing of insulin is a classic example of regulatory unintended consequences. It’s regarded as a drug in the US, but because of the nature of the product it is impossible to produce a “generic” insulin. In Europe it is regulated as a biological product (which it is), opening the way to demonstrate that “generics” (biosimilars, technically) are as good as without demonstrating they are identical at the molecular level. In the US that route is not open to “generic” competitors to the 3 big insulin manufacturers.
The FDA will catch up with the rest of the world next year and you will see sensible insulin prices in the US from around 2021/2022 onwards.
I guess beer is owed…..